Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Issue Archive

Table of Contents

BLOOD COMMENTARIES

PLENARY PAPER

In a Plenary Paper, Young et al describe impressive favorable outcomes of emicizumab prophylaxis in children with hemophilia A and factor VIII inhibitors, reporting a 99% reduction in annualized bleeding, with 77% of patients having no treated bleeding events.

REVIEW ARTICLE

Koyama and Hill review the role of the gut microbiome interaction with pretransplant conditioning injury in stimulating graft-versus-host disease.

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Gardner et al report that early intervention with tocilizumab and steroids at the first signs of mild cytokine release syndrome (CRS) following CD19 chimeric antigen receptor (CAR) T-cell infusion for B-cell acute lymphocytic leukemia reduces the development of life-threatening severe CRS without having a negative impact on antileukemic effect.

LYMPHOID NEOPLASIA

Catalina Amador,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Timothy C. Greiner,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Tayla B. Heavican,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Lynette M. Smith,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Karen Tatiana Galvis,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Waseem Lone,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Alyssa Bouska,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Francesco D’Amore,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Martin Bjerregaard Pedersen,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Stefano Pileri,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Claudio Agostinelli,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Andrew L. Feldman,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Andreas Rosenwald,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,German Ott,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Anja Mottok,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Kerry J. Savage,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Laurence de Leval,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Philippe Gaulard,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Soon Thye Lim,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Choon Kiat Ong,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Sarah L. Ondrejka,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Joo Song,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Elias Campo,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Elaine S. Jaffe,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Louis M. Staudt,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Lisa M. Rimsza,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Julie Vose,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Dennis D. Weisenburger,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Wing C. Chan,on behalf of the Lymphoma/Leukemia Molecular Profiling Project,Javeed Iqbal,on behalf of the Lymphoma/Leukemia Molecular Profiling Project

One-third of peripheral T-cell lymphomas are “not otherwise specified” (PTCL-NOS), but they have been subdivided into 2 subgroups based on gene expression profiling. Amador and colleagues generated an immunohistochemical algorithm that parallels the molecular separation of PTCL-NOS and provides useful prognostic information.

MYELOID NEOPLASIA

There is increasing evidence that the metabolic regulation of acute myeloid leukemia (AML) cell growth interacts with epigenetic pathways of gene expression and differentiation. Jiang et al link inhibition of glucose metabolism to epigenetic changes and altered transcriptional pathways in leukemic cells and demonstrate synergy between simultaneously targeting metabolism and chromatin modifiers in suppression of AML.

Cohesin mutations are common in myeloid malignancy. Sasca et al elucidate the potential role of cohesin loss in myelodysplastic syndrome and acute myeloid leukemia (MDS/AML). They demonstrate that cohesin binding is critical for erythroid-specific gene expression and that reduction in cohesin impairs terminal erythroid maturation and promotes myeloid malignancy.

THROMBOSIS AND HEMOSTASIS

Renaud Prevel,for the French Reference Center for Thrombotic Microangiopathies,Claire Roubaud-Baudron,for the French Reference Center for Thrombotic Microangiopathies,Samuel Gourlain,for the French Reference Center for Thrombotic Microangiopathies,Matthieu Jamme,for the French Reference Center for Thrombotic Microangiopathies,Karine Peres,for the French Reference Center for Thrombotic Microangiopathies,Ygal Benhamou,for the French Reference Center for Thrombotic Microangiopathies,Lionel Galicier,for the French Reference Center for Thrombotic Microangiopathies,Elie Azoulay,for the French Reference Center for Thrombotic Microangiopathies,Pascale Poullin,for the French Reference Center for Thrombotic Microangiopathies,François Provôt,for the French Reference Center for Thrombotic Microangiopathies,Eric Maury,for the French Reference Center for Thrombotic Microangiopathies,Claire Presne,for the French Reference Center for Thrombotic Microangiopathies,Mohamed Hamidou,for the French Reference Center for Thrombotic Microangiopathies,Samir Saheb,for the French Reference Center for Thrombotic Microangiopathies,Alain Wynckel,for the French Reference Center for Thrombotic Microangiopathies,Aude Servais,for the French Reference Center for Thrombotic Microangiopathies,Stéphane Girault,for the French Reference Center for Thrombotic Microangiopathies,Yahsou Delmas,for the French Reference Center for Thrombotic Microangiopathies,Valérie Chatelet,for the French Reference Center for Thrombotic Microangiopathies,Jean-François Augusto,for the French Reference Center for Thrombotic Microangiopathies,Christiane Mousson,for the French Reference Center for Thrombotic Microangiopathies,Pierre Perez,for the French Reference Center for Thrombotic Microangiopathies,Jean-Michel Halimi,for the French Reference Center for Thrombotic Microangiopathies,Tarik Kanouni,for the French Reference Center for Thrombotic Microangiopathies,Alexandre Lautrette,for the French Reference Center for Thrombotic Microangiopathies,Anne Charvet-Rumpler,for the French Reference Center for Thrombotic Microangiopathies,Christophe Deligny,for the French Reference Center for Thrombotic Microangiopathies,Dominique Chauveau,for the French Reference Center for Thrombotic Microangiopathies,Agnès Veyradier,for the French Reference Center for Thrombotic Microangiopathies,Paul Coppo,for the French Reference Center for Thrombotic Microangiopathies

Prevel and colleagues examined the natural history of thrombotic thrombocytopenic purpura (TTP) in older adults, reporting that the geriatric TTP population experiences delayed diagnosis and more severe neurologic and renal impairment. Older patients also have greater short- and long-term mortality.

LETTERS TO BLOOD

Luzalba Sanoja-Flores,on behalf of the EuroFlow Consortium,Juan Flores-Montero,on behalf of the EuroFlow Consortium,Noemi Puig,on behalf of the EuroFlow Consortium,Teresa Contreras-Sanfeliciano,on behalf of the EuroFlow Consortium,Roberia Pontes,on behalf of the EuroFlow Consortium,Alba Corral-Mateos,on behalf of the EuroFlow Consortium,Omar García-Sánchez,on behalf of the EuroFlow Consortium,María Díez-Campelo,on behalf of the EuroFlow Consortium,Roberto José Pessoa de Magalhães,on behalf of the EuroFlow Consortium,Luis García-Martín,on behalf of the EuroFlow Consortium,José María Alonso-Alonso,on behalf of the EuroFlow Consortium,Aranzazú García-Mateo,on behalf of the EuroFlow Consortium,Carlos Aguilar-Franco,on behalf of the EuroFlow Consortium,Jorge Labrador,on behalf of the EuroFlow Consortium,Abelardo Barez-García,on behalf of the EuroFlow Consortium,Angelo Maiolino,on behalf of the EuroFlow Consortium,Bruno Paiva,on behalf of the EuroFlow Consortium,Jesús San Miguel,on behalf of the EuroFlow Consortium,Elaine Sobral da Costa,on behalf of the EuroFlow Consortium,Marcos González,on behalf of the EuroFlow Consortium,María Victoria Mateos,on behalf of the EuroFlow Consortium,Brian Durie,on behalf of the EuroFlow Consortium,Jacques J. M. van Dongen,on behalf of the EuroFlow Consortium,Alberto Orfao,on behalf of the EuroFlow Consortium

BLOOD WORK

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals